Lida A. Mina

Hematology | Oncology

5777 E Mayo Blvd
Phoenix, AZ 85054

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 46 publications

Advancing the Oncology Data Paradigm: Multisite Expansion of Structured Cancer Data Capture at the Point of Care.

Advancing the Oncology Data Paradigm: Multisite Expansion of Structured Cancer Data Capture at the Point of Care.

Journal: JCO oncology practice

Published: July 02, 2026

Complete Imaging Resolution of Ductal Carcinoma In Situ During Osimertinib Therapy for Synchronous EGFR Exon 19-Mutant Non-Small Cell Lung Cancer: A Case Report.

Complete Imaging Resolution of Ductal Carcinoma In Situ During Osimertinib Therapy for Synchronous EGFR Exon 19-Mutant Non-Small Cell Lung Cancer: A Case Report.

Journal: International journal of molecular sciences

Published: May 26, 2026

Real-World Analysis of Adverse Events in Patients With Triple-Negative Breast Cancer Receiving Therapy per KEYNOTE-522.

Real-World Analysis of Adverse Events in Patients With Triple-Negative Breast Cancer Receiving Therapy per KEYNOTE-522.

Journal: JCO oncology practice

Published: May 05, 2026

Human epidermal growth factor receptor 2 (HER2) expression dynamics between diagnosis and recurrence in patients with breast cancer using artificial intelligence and electronic health records: the RosHER study.

Human epidermal growth factor receptor 2 (HER2) expression dynamics between diagnosis and recurrence in patients with breast cancer using artificial intelligence and electronic health records: the RosHER study.

Journal: ESMO real world data and digital oncology

Published: February 06, 2026

Pleomorphic Adenoma of the Breast Interpreted as Metaplastic Carcinoma: Awareness of a Rare Entity to Avoid Overtreatment.

Pleomorphic Adenoma of the Breast Interpreted as Metaplastic Carcinoma: Awareness of a Rare Entity to Avoid Overtreatment.

Journal: International journal of surgical pathology

Published: November 14, 2025

Erratum: Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence Round.

Erratum: Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence Round.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 02, 2025

Comparing [18F]FDG-positron emission tomography and breast magnetic resonance imaging to predict pathological complete response and 3-year invasive disease-free survival in HER2-positive early breast cancer patients: an unplanned exploratory analysis of the PHERGain trial.

Comparing [18F]FDG-positron emission tomography and breast magnetic resonance imaging to predict pathological complete response and 3-year invasive disease-free survival in HER2-positive early breast cancer patients: an unplanned exploratory analysis of the PHERGain trial.

Journal: ESMO open

Published: February 28, 2025

Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence Round.

Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence Round.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 26, 2024

Real-World Evidence on Prescribing Patterns and Clinical Outcomes of Metastatic Breast Cancer Patients Treated with PARP Inhibitors: The Mayo Clinic Experience.

Real-World Evidence on Prescribing Patterns and Clinical Outcomes of Metastatic Breast Cancer Patients Treated with PARP Inhibitors: The Mayo Clinic Experience.

Journal: Clinical breast cancer

Published: June 22, 2024

QTc prolongation across CDK4/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials.

QTc prolongation across CDK4/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials.

Journal: JNCI cancer spectrum

Published: May 07, 2024

Phase 2 trial of imprime and pembrolizumab immunotherapy in metastatic triple negative breast cancer patients who have progressed beyond first line chemotherapy.

Phase 2 trial of imprime and pembrolizumab immunotherapy in metastatic triple negative breast cancer patients who have progressed beyond first line chemotherapy.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: April 19, 2024

Factors influencing U.S. women's interest and preferences for breast cancer risk communication: a cross-sectional study from a large tertiary care breast imaging center.

Factors influencing U.S. women's interest and preferences for breast cancer risk communication: a cross-sectional study from a large tertiary care breast imaging center.

Journal: BMC women's health

Published: April 17, 2024

Showing 1-12 of 46

Last Updated: 09/26/2026